Literature DB >> 17261601

Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum.

Gregory M Glenn1, Christina P Villar, David C Flyer, A Louis Bourgeois, Robin McKenzie, Robert M Lavker, Sarah A Frech.   

Abstract

Transcutaneous immunization allows safe delivery of native heat-labile enterotoxin (LT) from Escherichia coli via application of a simple patch. Physical disruption of the stratum corneum can improve the efficiency of delivery. In the current study, the stratum corneum was disrupted using an electrocardiogram prep pad prior to patch application. The effects were quantified using transepidermal water loss (TEWL) and were correlated with the immune responses. Sixty adults received 50 microg of LT from three lots of LT (20 adults per group) administered in a patch on days 0 and 21. The immunizations were well tolerated. There were no differences in the anti-LT immunoglobulin G (IgG) titers between the three LT lots; the seroconversion rate was 100%, and the mean anti-LT IgG titer was 12,185 enzyme-linked immunosorbent assay units (EU) (a 24-fold increase). TEWL measurements obtained at the time of the second immunization were found to correlate with the day 42 individual increases in the anti-LT IgG titer (r = 0.59, P < 0.001). In a comparative assessment of the immune responses, sera after an LT+ ST+ (E2447A) oral ETEC challenge, which induced moderate to severe diarrhea in 81% of the recipients, had anti-LT IgG titers of 3,245 EU (a 10.8-fold increase). Similarly, the anti-LT IgG titer after administration of an oral cholera toxin B subunit-containing cholera vaccine, which cross-reacts with LT and protects against LT and LT/heat-stable toxin ETEC disease in the field, was 6,741 EU (a 3.3-fold increase). This study confirmed that a well-tolerated regimen for stratum corneum disruption before vaccine patch application results in robust immunity comparable to natural immunity and vaccine-induced immunity and that the magnitude of stratum corneum disruption correlates with the immune response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17261601      PMCID: PMC1865773          DOI: 10.1128/IAI.01740-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  Protection from natural infections with enterotoxigenic Escherichia coli: longitudinal study.

Authors:  Hans Steinsland; Palle Valentiner-Branth; Håkon K Gjessing; Peter Aaby; Kåre Mølbak; Halvor Sommerfelt
Journal:  Lancet       Date:  2003-07-26       Impact factor: 79.321

Review 2.  Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin.

Authors:  Gregory M Glenn; Richard T Kenney; Larry R Ellingsworth; Sarah A Frech; Scott A Hammond; J Paul Zoeteweij
Journal:  Expert Rev Vaccines       Date:  2003-04       Impact factor: 5.217

Review 3.  Bacterial toxins as mucosal adjuvants.

Authors:  L C Freytag; J D Clements
Journal:  Curr Top Microbiol Immunol       Date:  1999       Impact factor: 4.291

4.  The impact of infant feeding patterns on infection and diarrheal disease due to enterotoxigenic Escherichia coli.

Authors:  K Long; E Vasquez-Garibay; J Mathewson; J de la Cabada; H DuPont
Journal:  Salud Publica Mex       Date:  1999 Jul-Aug

5.  Antitoxic immunity in experimental cholera: protection, and serum and local antibody responses in rabbits after enteral and parenteral immunization.

Authors:  J Holmgren; A M Svennerholm; O Ouchterlony; A Anderson; G Walletström; U Westerberg-Berndtsson
Journal:  Infect Immun       Date:  1975-12       Impact factor: 3.441

6.  Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico.

Authors:  Pablo C Okhuysen; Zhi Dong Jiang; Lily Carlin; Charles Forbes; Herbert L DuPont
Journal:  Am J Gastroenterol       Date:  2004-09       Impact factor: 10.864

7.  Toxins and colonization factor antigens of enterotoxigenic Escherichia coli among residents of Jakarta, Indonesia.

Authors:  B A Oyofo; D S Subekti; A M Svennerholm; N N Machpud; P Tjaniadi; T S Komalarini; B Setiawan; J R Campbell; A L Corwin; M Lesmana
Journal:  Am J Trop Med Hyg       Date:  2001-08       Impact factor: 2.345

8.  Development of pathogenicity-driven definitions of outcomes for a field trial of a killed oral vaccine against enterotoxigenic Escherichia coli in Egypt: application of an evidence-based method.

Authors:  John Clemens; Stephen Savarino; Remon Abu-Elyazeed; Mohammad Safwat; Malla Rao; Thomas Wierzba; Ann-Marie Svennerholm; Jan Holmgren; Robert Frenck; Eunsik Park; Abdollah Naficy
Journal:  J Infect Dis       Date:  2004-05-25       Impact factor: 5.226

9.  Induction of protective immunity against lethal anthrax challenge with a patch.

Authors:  Richard T Kenney; Jianmei Yu; Mimi Guebre-Xabier; Sarah A Frech; Adam Lambert; Barbara A Heller; Larry R Ellingsworth; James E Eyles; E Diane Williamson; Gregory M Glenn
Journal:  J Infect Dis       Date:  2004-07-13       Impact factor: 5.226

10.  Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously.

Authors:  Fernando Güereña-Burgueño; Eric R Hall; David N Taylor; Frederick J Cassels; Daniel A Scott; Marcia K Wolf; Zachary J Roberts; Galina V Nesterova; Carl R Alving; Gregory M Glenn
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

View more
  17 in total

Review 1.  The Current State of Epicutaneous Immunotherapy for Food Allergy: a Comprehensive Review.

Authors:  Bruce J Lanser; Donald Y M Leung
Journal:  Clin Rev Allergy Immunol       Date:  2018-10       Impact factor: 8.667

2.  Facilitation of transcutaneous drug delivery and vaccine immunization by a safe laser technology.

Authors:  Xinyuan Chen; Dilip Shah; Garuna Kositratna; Dieter Manstein; Richard R Anderson; Mei X Wu
Journal:  J Control Release       Date:  2012-01-09       Impact factor: 9.776

3.  The extent of the uptake of plasmid into the skin determines the immune responses induced by a DNA vaccine applied topically onto the skin.

Authors:  Zhen Yu; Woon-Gye Chung; Brian R Sloat; Christiane V Löhr; Richard Weiss; B Leticia Rodriguez; Xinran Li; Zhengrong Cui
Journal:  J Pharm Pharmacol       Date:  2011-02       Impact factor: 3.765

4.  Concomitant enterotoxigenic Escherichia coli infection induces increased immune responses to Vibrio cholerae O1 antigens in patients with cholera in Bangladesh.

Authors:  Fahima Chowdhury; Yasmin A Begum; Mohammad Murshid Alam; Ashraful I Khan; Tanvir Ahmed; M Saruar Bhuiyan; Jason B Harris; Regina C LaRocque; Abu S G Faruque; Hubert Endtz; Edward T Ryan; Alejandro Cravioto; Ann-Mari Svennerholm; Stephen B Calderwood; Firdausi Qadri
Journal:  Infect Immun       Date:  2010-02-22       Impact factor: 3.441

5.  New Developments in Traveler's Diarrhea.

Authors:  Javier de la Cabada Bauche; Herbert L Dupont
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-02

Review 6.  Recent advances in understanding enteric pathogenic Escherichia coli.

Authors:  Matthew A Croxen; Robyn J Law; Roland Scholz; Kristie M Keeney; Marta Wlodarska; B Brett Finlay
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

7.  Travelers' diarrhea: an update on susceptibility, prevention, and treatment.

Authors:  Miguel M Cabada; A Clinton White
Journal:  Curr Gastroenterol Rep       Date:  2008-10

8.  Selective removal of stratum corneum by microdermabrasion to increase skin permeability.

Authors:  Harvinder S Gill; Samantha N Andrews; Senthilkumar K Sakthivel; Andrew Fedanov; Ifor R Williams; David A Garber; Frances H Priddy; Seth Yellin; Mark B Feinberg; Silvija I Staprans; Mark R Prausnitz
Journal:  Eur J Pharm Sci       Date:  2009-06-25       Impact factor: 4.384

9.  The A subunit of Escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes IgG2a, IgA, and Th17 responses to vaccine antigens.

Authors:  Elizabeth B Norton; Louise B Lawson; Zaid Mahdi; Lucy C Freytag; John D Clements
Journal:  Infect Immun       Date:  2012-04-23       Impact factor: 3.441

10.  A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunization.

Authors:  David I Bernstein; Marcela F Pasetti; Rebecca Brady; Amanda D Buskirk; Rezwanul Wahid; Michelle Dickey; Mitchell Cohen; Holly Baughman; Jill El-Khorazaty; Nicole Maier; Marcelo B Sztein; Shahida Baqar; A Louis Bourgeois
Journal:  Vaccine       Date:  2018-12-15       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.